Avidity Biosciences Exits S&P Indices Amid Strategic Shift and Novartis Deal

The removal of Avidity Biosciences (RNAM) from the S&P Global BMI and S&P TMI indices marks a critical technical juncture for the San Diego-based biotechnology firm. Announced on March 3, 2026, these deletions typically occur during quarterly or semi-annual index rebalancing when a constituent no longer meets specific market capitalization, liquidity, or float-adjusted requirements. For Avidity, a leader in RNA therapeutics, this move triggers a mandatory divestment cycle from passive investment vehicles, including exchange-traded funds (ETFs) and mutual funds that track these broad-market benchmarks.

Contextually, the index deletion arrives just days after a major corporate development: the closing of a deal with Novartis on February 27, 2026. This transaction involved the launch of Atrium Therapeutics, a spinout focused on rare cardiovascular diseases. While such deals are fundamentally positive—providing non-dilutive capital and validating the company's proprietary Antibody Oligonucleotide Conjugate (AOC) platform—they can also lead to shifts in share structure or market valuation that influence index eligibility. The timing suggests that the S&P Dow Jones Indices' decision may be a lagging response to these structural changes or a reflection of recent market volatility affecting the company's total market cap.

“

Contextually, the index deletion arrives just days after a major corporate development: the closing of a deal with Novartis on February 27, 2026.

From a market mechanics perspective, index deletions often result in the 'index effect,' where a stock experiences downward pressure leading up to and on the effective date of removal. Passive managers are forced to sell their holdings to maintain tracking accuracy, often creating a liquidity vacuum that active traders may exploit. For a mid-cap biotech like Avidity, where institutional ownership is a significant driver of price stability, the loss of these index-driven flows could increase short-term volatility. However, historical data suggests that for high-growth biotech entities, fundamental clinical catalysts usually outweigh technical index adjustments in the medium to long term.